RTP Mobile Logo
Oncology Grand Rounds Series: Acute Myeloid Leukemia (Webinar Audio Proceedings) — an NCPD-Accredited Program for Nurses
Released May 2021

Proceedings from the third in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Courtney D DiNardo and Eytan M Stein on cases from the practices of Ms Ilene Galinsky and Ms Sonia Glennie. (Audio Program)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of acute myeloid leukemia (AML).

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to to facilitate the optimal care of patients with acute myeloid leukemia.

    LEARNING OBJECTIVES

    • Recognize the clinical and prognostic significance of specific cytogenetic and molecular abnormalities in patients with acute myeloid leukemia (AML), and understand the rationale for diagnostic testing.
    • Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of AML.
    • Recognize the FDA approval of venetoclax in combination with a hypomethylating agent or low-dose cytarabine for patients with newly diagnosed AML who are 75 years or older or not eligible for intensive therapy, and discern how these regimens can be optimally integrated into nonresearch care algorithms.
    • Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to counsel patients with AML with FLT3 mutations regarding personalized treatment recommendations and research opportunities.
    • Develop an understanding of the available data with and current role of available IDH1/2 inhibitors for patients with newly diagnosed or relapsed/refractory AML and IDH1 or 2 mutations.
    • Consider Phase III data documenting the efficacy of CC-486 as maintenance therapy for patients with newly diagnosed AML who achieved first complete response or complete response with incomplete blood count recovery with induction chemotherapy, and discern how this novel strategy can be appropriately employed in clinical care.
    • Recall promising agents and combination strategies under investigation for AML, and counsel appropriately selected patients regarding clinical trial enrollment.

    ACCREDITATION STATEMENT
    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT
    NCPD credit is no longer available for this issue

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSAML2021/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    FOR SUCCESSFUL COMPLETION
    Audio Program: This NCPD activity consists of an audio component.
    NCPD credit is no longer available for this issue

    Video Program: This NCPD activity consists of a video component.
    NCPD credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    Courtney D DiNardo, MD, MSCE
    Associate Professor, Department of Leukemia
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Foghorn Therapeutics, Gilead Sciences Inc, Immune-Onc Therapeutics Inc, Novartis, Takeda Oncology; Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Astex Pharmaceuticals, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Cleave Therapeutics, Daiichi Sankyo Inc, Immune-Onc Therapeutics Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Scientific Advisory Board with Stock Options: Notable Labs.

    Eytan M Stein, MD
    Assistant Attending Physician
    Director, Program for Drug Development in Leukemia
    Leukemia Service, Department of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: AbbVie Inc, Agios Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Novartis, Ono Pharmaceutical Co Ltd, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Bayer HealthCare Pharmaceuticals, BioTheryX Inc, Bristol-Myers Squibb Company, Celgene Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Prelude Therapeutics, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc.

    Oncology Nurse Practitioners

    Ilene Galinsky, NP
    Senior Adult Leukemia Program Research Nurse Practitioner
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Sonia Glennie, ARNP, MSN, OCN
    Swedish Cancer Institute Center for Blood Disorders
    Seattle, Washington

    Speakers Bureau: Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc and Genentech, a member of the Roche Group.

    Release date: June 2021
    Expiration date: June 2022

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):